CLSD Clearside Biomedical Inc
Price (delayed)
$0.93
Market cap
$71.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.47
Enterprise value
$104.19M
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS
Highlights
The EPS has grown by 11% year-on-year but it has declined by 4.4% since the previous quarter
CLSD's equity has dropped by 144% year-on-year and by 12% since the previous quarter
The company's gross profit has shrunk by 81% YoY and by 80% QoQ
Key stats
What are the main financial stats of CLSD
Market
Valuations
Earnings
Shares outstanding
77.14M
Market cap
$71.74M
Enterprise value
$104.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
41.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62.62
Revenue
$1.66M
Gross profit
$1.52M
Operating income
-$28.88M
Net income
-$34.35M
EBIT
-$34.35M
EBITDA
-$34.13M
Free cash flow
-$25.68M
Per share
Balance sheet
Liquidity
EPS
-$0.47
EPS diluted
-$0.47
Free cash flow per share
-$0.35
Book value per share
-$0.51
Revenue per share
$0.02
TBVPS
$0.34
Total assets
$25.13M
Total liabilities
$63.98M
Debt
$52.47M
Equity
-$38.86M
Working capital
$16.48M
Debt to equity
-1.35
Current ratio
4.44
Quick ratio
4.28
Net debt/EBITDA
-0.95
Margins
Efficiency
Dividend
EBITDA margin
-2,050.8%
Gross margin
91%
Net margin
-2,064.4%
Operating margin
-1,735.7%
Return on assets
-107%
Return on equity
N/A
Return on invested capital
-64.2%
Return on capital employed
-169%
Return on sales
-2,064.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLSD stock price
How has the Clearside Biomedical stock price performed over time
Intraday
2.47%
1 week
-8.82%
1 month
8.18%
1 year
-33.57%
YTD
-2.11%
QTD
1.32%
Financial performance
How have Clearside Biomedical's revenue and profit performed over time
Revenue
$1.66M
Gross profit
$1.52M
Operating income
-$28.88M
Net income
-$34.35M
Gross margin
91%
Net margin
-2,064.4%
The company's gross profit has shrunk by 81% YoY and by 80% QoQ
The revenue has plunged by 80% YoY and by 78% from the previous quarter
The operating income has contracted by 16% YoY and by 10% from the previous quarter
CLSD's gross margin is down by 9% from the previous quarter and by 4.9% YoY
Growth
What is Clearside Biomedical's growth rate over time
Valuation
What is Clearside Biomedical stock price valuation
P/E
N/A
P/B
N/A
P/S
41.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62.62
The EPS has grown by 11% year-on-year but it has declined by 4.4% since the previous quarter
CLSD's equity has dropped by 144% year-on-year and by 12% since the previous quarter
The P/S is 101% above the last 4 quarters average of 20.0 and 47% above the 5-year quarterly average of 27.3
The revenue has plunged by 80% YoY and by 78% from the previous quarter
Efficiency
How efficient is Clearside Biomedical business performance
The company's return on assets fell by 25% YoY and by 15% QoQ
Clearside Biomedical's return on invested capital has increased by 23% YoY
Dividends
What is CLSD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLSD.
Financial health
How did Clearside Biomedical financials performed over time
The company's total assets is 61% lower than its total liabilities
The total liabilities is up by 28% YoY
The company's total assets fell by 26% YoY and by 14% QoQ
CLSD's equity has dropped by 144% year-on-year and by 12% since the previous quarter
The debt to equity has soared by 50% YoY and by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.